321. Raveendran J, Gangadharan D, Bayry J and Rasheed PA. 2025.Emerging trends in the Cystatin C sensing technologies: towards better chronic kidney disease management. RSC Advances 15 (7): 4926-4944.

320. Gayathri VG, Richard B, Chacko JT, Bayry J and Rasheed PA. 2025. Non-Ti MXenes: new biocompatible and biodegradable candidates for biomedical   applications. Journal of Materials Chemistry B 13(4):1212-1228.

318. Dellière S, Chauvin C, Wong SSW, Gressler M, Possetti V, Parente R, Fontaine T, Krüeger T, Kniemeyer O, Bayry J, Carvalho A, Brakhage AA, Inforzato A, Latgé JP and Aimanianda V. 2024. Interplay between host humoral pattern recognition molecules controls undue immune responses against Aspergillus fumigatus.                     Nature Communications 15 (1): 6966.

317. Kothari M, Kannan K, Sahadevan R, Retnakumar SV, Chauvin C, Bayry J and Sadhukhan S. 2024. Lipophilic derivatives of EGCG as potent α-amylase and α-        glucosidase inhibitors ameliorating oxidative stress and inflammation. Bioorganic Chemistry 153: 107786.

316. Guilloux K, Hegde P, Wong SSW, Aimanianda V, Bayry J*, Latgé JP*. 2024. Comparative analysis of the Aspergillus fumigatus cell wall modification and ensuing  human dendritic cell responses by β-(1,3)-Glucan synthase inhibitors-caspofungin and enfumafungin. Mycopathologia 189 (5):86.

315. Das C, Raveendran J, Bayry J, Rasheed PA. 2024. Selective and naked eye colorimetric detection of creatinine through aptamer-based target-induced     passivation of gold nanoparticles. RSC Advances 14:33784-33793.

314. Chakraborty A, Bayry J* and Mukherjee S*. 2024. Helminth-derived biomolecules as potential therapeutics against Ulcerative Colitis. Immunotherapy 16: 635-640.

313. Nazeer SS, Venkataraman RK, Jayasree RS and Bayry J. 2024. Infrared Spectroscopy for Rapid Triage of Cancer Using Blood Derivatives: A Reality Check. Analytical Chemistry 96: 957-965.

312. Bayry J. 2024. Human basophil response to SARS-CoV-2. VIROCON 2024 Conference proceedings.  VIROCON- 2024. International conference on Emerging Viruses: Pandemic and Biosecurity Perspectives. November 11-13. DRDO- Defence Research & Development Establishment (DRDE), Gwalior, 2024. P41-45

311. Bayry J. 2024. Immune evasion by the pathogen. Conference Proceedings. XXIX Annual convention of ISVIB and National Conference on “Challenges in Animal Health and Production amidst Climate Change: Innovative, Sustainable Solutions and their Translations” 26-28 September, 2024. P55-59

310.  Bayry J. 2024. Forward. Book: Regulatory T Cells and Autoimmune Diseases 1: xxxiii-xxxiv. https://www.sciencedirect.com/science/article/pii/ B9780443139475000087  (Elsevier) (https://www.sciencedirect.com/book/9780443139475/regulatory-t-cells-and-autoimmune-diseases) 

309. Sharma C and Bayry J. 2023. High risk of autoimmune diseases after COVID-19. Nature Reviews Rheumatology 19:399-400.

308. Bonam SR, Platenburg PP and Bayry J*. 2023. Retrospective analysis on the immunopotentiating mechanism of an emulsion-based vaccine adjuvant on human antigen presenting cells. Frontiers in Immunology13:1086752.

307. Bayry J*, Ahmed E, Toscana-Rivera D, Vonneissen N, Genest G, Cohen C, Dembele M, Kaveri SV and Mazer BD*. 2023. Intravenous immunoglobulin: mechanism of action in autoimmune and inflammatory conditions. The Journal of Allergy and Clinical Immunology. In Practice 11: 1688-169.

306. ChauvinC, Levillayer L, Roumier M, Nielly H, Roth C, Karnam A, Bonam SR, Bourgarit A, Dubost C, Bousquet A, le Burel S, Mestiri R, Sene D, Galland J, Vasse M, Groh M, le Marchand M, Vassord-Dang C, Gautier J-F, Pham-Thi N, Verny C, Pitard B, Planchais C, Mouquet H, Paul R, Simon-Loriere E, Bayry J*, Gilardin L* and Sakuntabha A*. 2023. Tocilizumab treated convalescent COVID-19 patients retain the cross-neutralization potential against SARS-CoV-2 variants. iScience 26:1086752.

305. Chauvin C, Retnakumar SV and Bayry J*. 2023. Obesity negatively impacts maintenance of antibody response to COVID-19 vaccines. Cell Reports Medicine 4:101117.

304. Hachem CE, Marschall P, Hener P, Karnam A, Bonam SR, Meyer P, Flatter E, Birling M-C, Bayry J and Li M. 2023.  IL-3 produced by T cells is crucial for basophil extravasation in hapten-induced allergic contact dermatitis. Frontiers in Immunology 14: 1151468

303. Retnakumar SV, Chauvin C, and Bayry J*. 2023. The implication of anti-PD-1 therapy in cancer patients for the vaccination against viral and other infectious diseases. Pharmacology & Therapeutics 245: 108399.

302. Das NC, Chakraborty P, Bayry J* and Mukherjee S*. 2023 Comparative binding ability of human monoclonal antibodies against Omicron variants of SARS- CoV-2: An in silico investigation. Antibodies 12:17.

301. Chauvin C, Retnakumar SV and Bayry J*. 2023. Gasdermin D as a cellular switch to orientate immune responses via IL-33 or IL-1β. Cellular & Molecular Immunology 20:8-10.

300. Retnakumar SV, Bonam SR, Hu H and Bayry J*. 2023. Vaccines and Vaccine Adjuvants/Immunomodulators for Infectious Diseases. Vaccines. 11:383.

299. Chakraborty A, Bayry J* and Mukherjee S*. 2023. Immunoinformatics approaches in designing vaccines against COVID-19. Methods in Molecular Biology 2673:431-452.

298. Chauvin C and Bayry J*. 2022. Basophils orchestrate kidney fibrosis. Cell Research 32: 713-714.

297. Bonam SR, Chauvin C, Levillayer L, Mathew MJ, Sakuntabhai A and Bayry J*. 2022. SARS-CoV-2 induces cytokine responses in human basophils. Frontiers in Immunology 12: 838448.

296. Bonam SR, Chauvin C, Mathew MJ and Bayry J*. 2022. IFN-γ induces PD-L1 expression in primed human basophils. Cells 11: 801.

295. Das NC, Chakraborty P, Bayry J* and Mukherjee S*. 2022. In silico analyses on the comparative potential of therapeutic human monoclonal antibodies against newly emerged SARS-CoV-2 variants bearing mutant spike protein. Frontiers in Immunology 12:782506.

294. Al-Sayyar A, Hulme KD, Thibaut R, Bayry J, Sheedy FJ, Short KR and Alzaid F. 2022. Respiratory tract infections in diabetes – lessons from tuberculosis and influenza to guide understanding of COVID-19 severity. Frontiers in Endocrinology. 13 : 919223.

293. Bonam SR, Hu H and Bayry J*. 2022. Role of the PD-1 and PD-L1 axis in COVID-19. Future Microbiology. 17: 985-988.

292. Kumar D, Bayry J and Hegde NR. 2022. COVID-19: A Veterinary and One Health Perspective. Journal of the Indian Institute of Science 102: 689-709.

291. Stanworth S, Brand A, Kaveri SV, Vrielink H, Greinacher A, Domanovic D, von Lindern M, Allard S, Bayry J, Bohonek M, Buser A, Claas FHJ, Knutson F, Lozano M, Olsson ML, Pirenne F, Rebulla P, So-Osman C, Tissot J-D, Toye AM, Ushiro-Lumb I, van den Akker E and Zeerleder S. 2022. The EHA Research oadmap: Transfusion Medicine. HemaSphere 6: e670.

290. Fouquet G, Marié C, Collet L, Vilpoux C, Ouled-Haddou H, Ngu-yen-Khac E, Bayry J, Naassila M, Marcq I and Bouhlal H. 2022. Rescuing SLAMF3 expression restores sorafenib response in hepatocellular carcinoma cells through the induction of mesenchymal-to-epithelial transition. Cancers 14: 910.

289. Sharma VK and Bayry J*. 2022. Restoration of established systemic inflammation and autoimmunity by Foxp3+ regulatory T cells. Cellular & Molecular Immunology 19:133-135.

288. Sharma C, Ganigara M, Galeotti C, Burns J, Berganza F, Hayes D, Singh- Grewal D, Bharath S, Sajjan S, Bayry J*. 2021. Multisystem inflammatory syndrome in children and Kawasaki disease: a critical comparision. Nature Reviews Rheumatology 17:731-748.

287. Karnam A, Bonam SR, Rambabu N, Wong SSW, Aimanianda V, Bayry J*. 2021. Wnt-β-catenin signaling in human dendritic cells mediates regulatory T cell responses to fungi via the PD-L1 pathway. mBio 12: e02824-21.

286. Adeloye D, Elneima O, Daines L, Poinasamy K, Quint JK, Walker S, Brightling CE, Siddiqui S, Hurst JR, Chalmers JD, Pfeffer PE, Novotny P, Drake TM, Abdollahi M, Agarwal D, Al-Lehebi R, Barnes PJ, Bayry J, Bonay M, Bont LJ, Bourdin A, Brown T, Caramori G, Chan AHY, Dockrell DH, Doe S, Duckers J, D'Urzo A, Ekström M, Esteban C, Greene CM, Gupta A, Ingram JL, Khoo EM, San Ko FW, Koppelman GH, Lipworth BJ, Lisspers K, Loebinger M, Lopez-Campos JL, Maddocks M, Mannino D, Martinez-Garcia MA, Mcnamara R, Miravitlles M, Ndarukwa P, Pooler A, Rhee CK, Schwarz P, Shaw D, Steiner M, Tai A, Ulrik CS, Walker P, Williams M, Heaney LG, Rudan I, Sheikh A, and De Soyza A. International COVID-19 Airways Diseases Group. 2021. The long-term sequelae of COVID-19: an international consensus on research priorities for patients with pre-existing and new-onset airways disease Lancet Respiratory Medicine 9:1467-1478.

285. Ganigara M, Sharma C, Bayry J*. 2021. Unraveling the mechanisms of IVIG immunotherapy in MIS-C. Cell Reports Medicine 2:100431.

284. Saravanan S, Guleria N, Ranjitha HB, Sreenivasa BP, Hosamani M, Prieto C, UmapathiV, Santosh HK, Behera S, Dhanesh VV, Krishna GS, Gopinath S, Kolte A, Bayry J, Sanyal A and Basagoudanavar SH. 2021. Induction of antiviral and cell mediated immune responses significantly reduce viral load in an acute foot-and-mouth disease virus infection in cattle. Genomics 113:4254-4266.

283. Kotla NG, Bonam SR, Rasala S, Wankar J, Bohara RA, Bayry J, Rochev Y, Pandit A. 2021.  Recent advances and prospects of hyaluronan as a multifunctional therapeutic system. Journal of Controlled Release 336: 598-620.

282. Fogha J, Bayry J, Diharce J and de Brevern AG. 2021. Structural and evolutionary exploration of the IL-3 family and its alpha subunit receptors. Amino Acids 53:1211-1227.

281.  Bonam SR, Rénia L, Tadepalli G, Bayry J and Kumar HMS. 2021. Plasmodium falciparum malaria vaccines and vaccine adjuvants. Vaccines 9: 1072.

280. Karnam A, Lacroix-Desmazes S, Kaveri SV and Bayry J*. 2021. Vaccine-induced immune thrombotic thrombocytopenia: Consider IVIG batch in the treatment. Journal of Thrombosis & Haemostasis 19: 1838-1839.

279. Rambabu N, Mathew MJ, Kaveri SV, Bayry J*. 2021. Boolean analysis of the transcriptomic data to identify novel biomarkers of IVIG response. Autoimmunity Reviews 20:102850.

278. Bozza S, Iannitti RG, Pariano M, Renga G, Costantini C, Romani L*, Bayry J*. 2021. Small molecule CCR4 antagonists protect mice from Aspergillus infection and allergy. Biomolecules 11:351.

277. Nguyen A, Repesse Y, Ebbo M, Allenbach Y, Benveniste O, Vallat J-M, Magy L, Deshayes S, Maigne G, de Boysson H, Karnam A, Delignat S, Lacroix-Desmazes S, Bayry J, Aouba A. 2021. IVIg increases interleukin-11 levels, which in turn contribute to increased platelets, VWF and FVIII in mice and humans. Clinical & Experimental Immunology 204: 258-266.

276. Das NC, Ray AS, Bayry J*, Mukherjee S*. 2021. Therapeutic efficacy of anti-bestrophin antibodies against experimental filariasis: immunological, immune-informatics and immune-simulation investigations. Antibodies 10: 14.

275. Bourne JH, Beristain-Covarrubias N, Zuidscheroude M, Campos J, Di Y, Garlick E, Colicchia M, Terry LV, Thomas SG, Brill A, Bayry J, Watson SP, Rayes J. 2021. CLEC-2 prevents accumulation and retention of inflammatory macrophages during murine peritonitis. Frontiers in Immunology 12: 693974.

274. Pradhan VD, Khadilkar PV, Nadkar MY, Kini SH, Roumenina LT, Rajadhyaksha AG, Khan TA, Chougule D, Ghosh K, Bayry J, Kaveri S. 2021 Impact of Autoantibodies to Complement Components on the Disease Activity in SLE. The Journal of the Association of Physicians of India 69(4):11-12.

273. Klionsky DJ……Bayry J…… Tong CK. 2021. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition). Autophagy. 17: 1-382.

272. Wong SSW, Venugopalan LP, Beaussart A, Karnam A, Mohammed MRS, Jayapal JM, Bretagne S, Bayry J, Prajna L, Dharmalingam K, Latgé J-P, Aimanianda V. 2021. Species-specific immunological reactivities depend on the cell-wall organization of the two Aspergillus, Aspergillus fumigatus and A. flavus. Frontiers in Cellular and Infection Microbiology 11: 643312.

271. Bonam SR, Kotla NG, Bohara RA, Rochev Y, Webster TJ, Bayry J. 2021. Potential immuno-nanomedicine strategies to fight COVID-19 like pulmonary infections. Nano Today 36: 101051.

270.  Kumar D, Gauthami S, Bayry J, Kaveri SV, Hegde NR. 2021. Antibody therapy: from diphtheria to cancer, COVID-19 and beyond. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy 40:36-49.

269. Das M, Karnam A, Stephen-Victor E, Gilardin L, Bhatt B, Sharma VK, Rambabu N, Patil V, Lecerf M, Käsermann F, Bruneval P, Balaji K, Benveniste O, Kaveri SV, Bayry J*. 2020. Intravenous immunoglobulin mediates anti-inflammatory effects in peripheral blood mononuclear cells by inducing autophagy. Cell Death & Disease 11: 50.

268. Karnam A, Rambabu N, Das M, Bou-Jaoudeh M, Deligant S, Käsermann F, Lacroix-Desmazes S, Kaveri SV, Bayry J*. 2020. Therapeutic normal immunoglobulin G intravenous immunoglobulin activates Wnt-β-catenin pathway in dendritic cells. Communications Biology 3: 96

267. Galeotti C, Karnam A, Dimitrov JD, Chevailler A, Kaveri SV, Bayry J*. 2020. Anti-IgE IgG autoantibodies isolated from therapeutic normal IgG intravenous immunoglobulin induce basophil activation. Cellular & Molecular Immunology 17: 426-429.

266. Galeotti C, Karnam A, Das M, Kaveri SV, Bayry J*. 2020. Acid stripping of surface IgE antibodies bound to FcεRI is unsuitable for the functional assays that require long-term culture of basophils and entire removal of surface IgE. International Journal of Molecular Sciences 21: 510.

265. Danion F, Aimanianda V, Bayry J, Duréault A, Wong S, Bougnoux ME, Tcherakian C, Alyanakian MA, Guegan H, Puel A, Picard C, Lortholary O, Lanternier F, Latgé JP. 2020. Aspergillus fumigatus infection in humans with STAT3-deficiency is associated with defective interferon-g and Th17 responses. Frontiers in Immunology 11: 38.

264. Delignat S, Rayès J, Dasgupta S, Gangadharan B, Denis CV, Christophe OD, Bayry J, Kaveri SV, Lacroix-Desmazes S. 2020. Removal of mannose-ending glycan at Asn 2118 abrogates FVIII presentation by human monocyte-derived dendritic cells. Frontiers in Immunology 11: 393.

263. Saha C, Kothapalli P, Patil V, Reddy GBM, Kaveri SV, Bayry J*. 2020. Intravenous immunoglobulin suppresses the polarization of both classically and alternatively activated macrophages. Human Vaccines & Immunotherapeutics 16: 233-239.

262. Wong SSW, Daniel I, Gangneux J-P, Jayapal JM, Guegan H, Dellière S, Lalitha P, Shende R, Madan T, Bayry J, Guijarro I, Dharmalingam K, Aimanianda V. 2020. Differential interactions of serum and bronchoalveolar lavage complement proteins with conidia of airborne fungal pathogen Aspergillus fumigatus Infection & Immunity 88: e00212- 20.

261. Valsecchi V, Stephen-Victor E, Wong SSW, Karnam A, Sunde M, Guijarro JI, de Francisco BR, Krüger T, Kniemeyer O, Brown GD, Willment JA, Latgé JP, Brakhage AA, Bayry J*, Aimanianda V*. 2020. The role of RodA-conserved cysteine residues in the Aspergillus fumigatus conidial surface organization. Journal of Fungi 6: 151.

260. Planchais C, Rayes J, Delignat S, Pashova S, Varthaman A, Pashov A, Bayry J, Kaveri SV, Dimitrov JD, Lacroix-Desmazes S. 2020. Stimulation with FITC-labeled antigens confers B cells with regulatory properties. Cellular Immunology 354: 104151.

259. Fouque G, MariéC, Badaoui M, Demey B, Radoslavova S, Telliez M-S, Dhennin-Duthille I, Bayry J, Sevestre H, Ouadid-Ahidouch H, Marcq I, Bouhlal H. 2020. Mammary SLAMF3 regulates store-operated Ca2+ entry and migration through STIM1 in breast cancer cells and cell lines. Journal of Cancer Science and Clinical Therapeutics 4: 462-479.

258. Galeotti C, Bayry J. 2020*. Autoimmune and inflammatory diseases following COVID-19. Nature Reviews Rheumatology 16:413-414.

257. Bonam SR, Bayry J. 2020*. For antigen-specific effector or Foxp3+ regulatory T cell fate, cyclin-dependent kinases hold the trump card. Cellular & Molecular Immunology 17:310-312.

256. Bonam SR*, Muller S, Bayry J, Klionsky DJ. 2020. Autophagy as an emerging target for COVID-19: lessons from an old friend, chloroquine. Autophagy 16: 2260-66.

255. Das M, Stephen-Victor E, Bayry J*. 2020. Regulatory T cells do not suppress rather activate human basophils by IL-3 and STAT5-dependent mechanisms. Oncoimmunology 9: 1773193.

254. Galeotti C, Kaveri SV, Bayry J*. 2020. Intravenous immunoglobulin immunotherapy for coronavirus disease-19 (COVID-19). Clinical & Translational Immunology 9: e1198.

253. Alcazar-Fuoli L, Bayry J, Aimanianda V. 2020. Editorial: The role of the fungal cell wall in host-fungal interactions. Frontiers in Cellular and Infection Microbiology 10:392.

252. Bonam SR, Kaveri SV, Sakuntabhai A, Gilardin L, Bayry J*. 2020. Adjunct immunotherapies for the management of severely ill COVID-19 patients. Cell Reports Medicine 1: 100016.

251. Maddur MS, Lacroix-Desmazes S, Dimitrov JD, Kazatchkine MD, Bayry J, Kaveri SV. 2020. Natural Antibodies: from first line defense against pathogens to perpetual immune homeostasis. Clinical Reviews in Allergy and Immunology 58: 213-228.

250. Mimoun A, Delignat S, Peyron I, Daventure V, Lecerf M, Dimitrov JD, Kaveri SV, Bayry J, Lacroix-Desmazes S. 2020. Relevance of the materno-fetal interface for the induction of antigen-specific immune tolerance. Frontiers in Immunology 11:810.

249. Bonam SR, Bayry J, Tschan MP, Muller S. 2020. Progress and challenges in the use of MAP1LC3 as a legitimate marker for measuring dynamic autophagy in vivo. Cells 9: 1321.

248. Stephen-Victor E, Das M, Karnam A, Pitard B, Gautier J-F and Bayry J*. 2020. Potential of regulatory T cell-based therapies in the management of severe COVID-19. European Respiratory Journal 56: 2002182.

247. Galeotti C, Stephen-Victor E, Karnam A, Das M, Gilardin L, Maddur MS, Wymann S, Vonarburg C, Chevailler A, Dimitrov JD, Benveniste O, Bruhns P, Kaveri SV, Bayry J*. 2019. Intravenous immunoglobulin induces IL-4 in human basophils by signaling through surface-bound IgE. Journal of Allergy and Clinical Immunology 144: 524-535.

246. Bozza S, Käsermann F, Kaveri SV, Romani L, Bayry J*. 2019. Intravenous immunoglobulin protects from experimental allergic bronchopulmonary aspergillosis via a sialylation-dependent mechanism. European Journal of Immunology 49:195-198.

245. Mukherjee S, Karnam A, Das M, Sinha Babu SP, Bayry J*. 2019. Wuchereria bancrofti filaria activates human dendritic cells and polarizes T helper 1 and regulatory T cells via toll-like receptor 4. Communications Biology 2: 169.

244. Karnam A, Stephen-Victor E, Das M, Magy L, Vallat JM, Bolgert F, Simon-Loriere E, Kaveri SV, Sakuntabhai A, Bayry J*. 2019. Does intravenous immunoglobulin therapy in Guillain-Barré syndrome patients interfere with serological Zika detection? Autoimmunity Reviews 18:632-633.

243. Charlet R, Sendid B, Kaveri SV, Poulain D, Bayry J*, Jawhara S*. 2019. Intravenous immunoglobulin therapy eliminates Candida albicans and maintains intestinal homeostasis in a murine model of dextran sulfate sodium-induced colitis. International Journal of Molecular Sciences 20: E1473.

242. Valsecchi I, LaiJI, Stephen-Victor E, Pillé A, Beaussart A, Lo V, Pham CLL, Aimanianda V, Kwan AH, Duchateau M, Gianetto QG, Matondo M, Lahoux M, Sheppard M, Dufrene Y, Bayry J*, Guijarro JI*, Sunde M*, Latgé JP*. 2019. Assembly and disassembly of Aspergillus fumigatus conidial rodlets. Cell Surface 5: 100023.

241. Das M, Alzaid F, Bayry J*. 2019. Regulatory T cells under the mercy of mitochondia.  Cell Metabolism 29: 243-245.

240. Trinath J, Bayry J*. 2019. Current trends with FOXP3+ regulatory T cell immunotherapy to contest autoimmunity and inflammation. Immunotherapy 11: 755-758.

239. Sharma M, Das M, Stephen-Victor E, Galeotti C, Karnam A, Maddur MS, Bruneval P, Kaveri SV, Bayry J*. 2018. Regulatory T cells induce activation rather than suppression of human basophils. Science Immunology 3: eaan0829.

238. Maddur MS, Kaveri SV, Bayry J*. 2018. Induction of human dendritic cell maturation by naïve and memory B-cell subsets requires different activation stimuli. Cellular & Molecular Immunology 15: 1074-1076.

237. BeziaudL, BoullerotL, TranT, MansiL, Marie-JosephEL, RavelP, JohannesL, BayryJ, TartourE, AdotéviO.  2018. Rapalog combined with CCR4 antagonist improves anticancer vaccines efficacy. International Journal of Cancer 143: 3008-3018.

236. Wong SSW, Rani M, Dodagatta-Marri E, Ibrahim-Granet U, Kishore U, Bayry J, Latgé JP, Sahu A, Madan T, Aimanianda V. 2018. Fungal melanin stimulates surfactant protein D–mediated opsonization of and host immune response to Aspergillus fumigatus spores. Journal of Biological Chemistry 293:4901-4912.

235.Valsecchi I, Dupres V, Stephen-Victor E, Guijarro JI, Gibbons J, Beau R, Bayry J, Coppee JY, Lafont F, Latgé JP, Beauvais A. 2018. Role of hydrophobins in Aspergillus fumigatus. Journal of Fungi 4:2.

234. Pradhan V, Pandit P, Surve P, Lecerf M, Rajadhyaksha A, Nadkar M, Khadilkar PV, Chougule DA, Naigaonkar AA, Lacroix-Desmazes S, Bayry J, Ghosh K, Kaveri SV. 2018. Catalytic antibodies in patients with systemic lupus erythematosus. European Journal of Rheumaology 5: 173-178.

233. Stephen-Victor E, Bayry J*. 2018. Multimerized IgG1 Fc molecule as an anti-inflammatory agent. Nature Reviews Rheumatology 14: 390-392.

232. Bayry J*, Kaveri SV. 2018. Kill 'Em All: Efgartigimod immunotherapy for autoimmune diseases. Trends in Pharmacological Sciences 39:919-922.

231. Bayry J*. 2018. Indian researchers must resist predatory open-access journals. Nature 563:35.

230. João C, Negi VS, Kazatckine MD, Bayry J*, Kaveri SV*. 2018.  Passive serum therapy to immunomodulation by IVIG: A fascinating journey of antibodies. Journal of Immunology 200:1957-1963.

229. Humbert L, Cornu M, Proust-Lemoine E, Bayry J, Wemeau JL, Vantyghem MC, Sendid B. 2018. Chronic mucocutaneous candidiasis in autoimmune polyendocrine syndrome type 1. Frontiers in Immunology 9:2570.

228. Hegde NR*, Gauthami S, Sampath Kumar HM, Bayry J*. The use of databases, data mining and immunoinformatics in vaccinology: where are we? Expert Opinion on Drug Discovery 13:117-130.

227. Fouquet G, Marcq I, Debuysscher V, Bayry J, Singh AR, Bengrine A, Nguyen-Khac E, Naassila M, Bouhlal H. 2018. Signaling Lymphocytic Activation Molecules SLAM and cancers: friends or foes?  Oncotarget 9:16248-16262.

226. Rusch T, Bayry J, Werner J, ShevchenkoI, Bazhin AV. 2018. Immunotherapy as an option for cancer treatment. Archivum Immunologiae et Therapiae Experimentalis 66:89-96.

225. Stephen-Victor E, Das M, Sharma M, Galeotti C, Fohrer-Ting H, Sendid B, Darnige L, Terris B, Badoual C, Bruneval P, Kaveri SV, Bayry J*. 2017. Demystification of enigma on antigen presenting cell features of human basophils: data from secondary lymphoid organs. Haematologica 102: e233-e237.

224. Stephen-Victor E, Karnam A, Fontaine T, Beauvais A, Das M, Hegde P, Prakhar P, Holla S, Balaji KN, Kaveri SV, Latgé JP, Aimanianda V, Bayry J*. 2017. Aspergillus fumigatus cell wall α-(1,3)-glucan stimulates regulatory T cell polarization by inducing PD-L1 expression on human dendritic cells. Journal of Infectious Diseases 216:1281-1294.

223. Saha C, Das M, Patil V, Stephen-Victor E, Sharma M, Wymann S, Jordi M, Vonarburg C, Kaveri SV, Bayry J*. 2017. Monomeric immunoglobulin A from plasma inhibits human Th17 responses in vitro independent of FcαRI and DC-SIGN. Frontiers in Immunology 8: 275.

222. Maddur MS, Stephen-Victor E, Das M, Prakhar P, Sharma VK, Singh V, Rabin M, Trinath J, Balaji KN, Bolgert F, Vallat JM, Magy L, Kaveri SV, Bayry J*. 2017. Regulatory T cell frequency, but not plasma IL-33 levels represents potential immunological biomarker to predict clinical response to intravenous immunoglobulin therapy. Journal of Neuroinflammation 14: 58

221. Das M, Galeotti C, Stephen-Victor E, Karnam A, Kaveri SV, Bayry J*. 2017. Human basophils may not undergo modulation by DC-SIGN and mannose receptor-targeting immunotherapies due to absence of receptors. Journal of Allergy and Clinical Immunology 139:1403-1404.e1.

220. Klein A, Sagi-Assif O, Meshel T, Telerman A, Izraely S, Ben-Menachem S, Bayry J, Marzese D, Ohe S, Hoon D, Erez N, Witz I. 2017. CCR4 is a determinant of melanoma brain metastasis. Oncotarget 8:31079-31091.

219. Davies MN, Pere H, Bosschem I, Haesebrouck F, Flahou B, Tartour E, Flower DR, Tough DF, Bayry J*. 2017. In Silico Adjuvant Design and Validation. Methods in Molecular Biology 1494:107-125.

218. Maddur MS, Kaveri SV, Bayry J*. 2017. Circulating normal IgG as stimulator of regulatory T cells: lessons from intravenous immunoglobulin. Trends in Immunology 38:789-792.

217. Bayry J*. 2017. Harnessing the regulators to enhance viral vaccine efficacy. Future Medicinal Chemistry. 9: 1319-1321.

216. Galeotti C, Kaveri SV, Bayry J*. 2017. IVIG-mediated effector functions in autoimmune and inflammatory diseases. International Immunology 29: 491-498.

215. Stephen-Victor E, Bosschem I, Haesebrouck F, Bayry J*. 2017. The Yin and Yang of regulatory T cells in infectious diseases and avenues to target them. Cellular Microbiology 19: e12746.

214. Stephen-Victor E, Sharma VK, Das M, Karnam A, Saha C, Lecerf M, Galeotti C, Kaveri SV, Bayry J*. 2016. IL-1β but not programmed death-1 and programmed death-ligand pathway is critical for the human Th17 response to Mycobacterium tuberculosis. Frontiers in Immunology 7: 465.

213. Galeotti C, Hegde P, Das M, Stephen-Victor E, Canale F, Muñoz M, Sharma VK, Dimitrov JD, Kaveri SV, Bayry J*. 2016. Heme oxygenase-1 is dispensable for the anti-inflammatory activity of intravenous immunoglobulin. Scientific Reports 5: 19592.

212. Holla S, Stephen-Victor E, Prakhar P, Sharma M, Saha C, Udupa V, Kaveri SV, Bayry J*, Balaji KN. 2016*. Mycobacteria-responsive sonic hedgehog signaling mediates programmed death-ligand 1- and prostaglandin E2-induced regulatory T cell expansion. Scientific Reports 5: 24193.

211. Beziaud L, Mansi L, Ravel P, Marie-Joseph E, Laheurte C, Rangan L, Bonnefoy F, Pallandre J, Boullerot L, Gamonet C, Vrecko S, Queiroz L, Maurina T, Mouillet G, Tan Hon T, Curtit E, Royer B, Gaugler B, Bayry J, Tartour E, Thierry-Vuillemin A, Pivot X, Borg C, Godet Y and Adotévi O. 2016. Rapalogs efficacy relies on the modulation of antitumor T cell immunity. Cancer Research 76:4100-4112.

210. Engert A*, Balduini C, Brand A,…… Bayry J…….Schuringa JJ; EHA Roadmap for European Hematology Research. The European Hematology Association Roadmap for European Hematology Research: A Consensus Document. 101:115-208.

209. Hadzhieva M, Vassilev T, Bayry J, Kaveri SV, Lacroix-Desmazes S, Dimitrov JD. 2016. Relationship between natural and heme-mediated antibody polyreactivity. Biochemical and Biophysical Research Communications 472:281-286.

208. Saha C, Das M, Stephen-Victor E, Friboulet A, Bayry J*, Kaveri SV. 2016*. Differential effect of Viscum album preparations on the maturation and activation of human dendritic cells and CD4+ T cell response. Molecules 21:912.

207. Pinto P, Shetty S, Lacroix-Desmazes S, Bayry J, Kaveri S, Ghosh K. 2016. Antibody profile in Indian severe haemophilia A patients with and without FVIII inhibitors. Immunol Letters 169: 93-97.

206. Pradhan V, Pandit P, Rajadhyaksha A, Patwardhan M, Surve P, Kamble P, Lecerf M, Bayry J, Kaveri S, Ghosh K, Nadkar MY. 2016. Association of serum ferritin levels with hematological manifestations in systemic lupus erythematosus patients from western India. The Journal of the Association of Physicians of India 64:14-18.

205. Bayry J*. 2016. Repressing immunity in autoimmune disease. New England Journal of Medicine 374:2090-2092.

204. Bayry J*, Gautier JF. 2016. Regulatory T cell immunotherapy for type 1 diabetes: a step closer success? Cell Metabolism 23:231-233.

203. Shopsin B, Kaveri SV, Bayry J*. 2016. Tackling difficult Staphylococcus aureus infections: Antibodies show the way. Cell Host & Microbe 20:555-557.

202. Bayry J*. 2016. Lupus pathogenesis: role of IgE autoantibodies. Cell Research 26:271-272.

201. Stephen-Victor E, Fickenscher H, Bayry J*. 2016. IL-26: an emerging proinflammatory member of the IL-10 cytokine family with multifaceted actions in antiviral, antimicrobial and autoimmune responses. PLoS Pathogens 12: e1005624.

200. Sharma V, Kaveri SV, Bayry J. 2016. Impaired regulatory T cell function in autoimmune diseases: are microRNAs the culprits? Cellular & Molecular Immunology 13:135-137.

199. Bontempi I, Vicco MH, Bayry J*. 2016. Chronic Chagas disease: can prophylaxis and therapeutic vaccines crack this ‘hard nut’? Immunotherapy 8:99-101.

198. Galeotti C, Kaveri SV, Cimaz R, Koné-Paut I, Bayry J*. 2016. Predisposing factors, pathogenesis and therapeutic intervention of Kawasaki disease. Drug Discovery Today 21:1850-1857.

197. Kohler H, Bayry J, Kaveri SV. 2016. The homophilic domain-an immunological archetype. Frontiers in Immunology 7:106.

196. Galeotti C, Stephen-Victor E, Sharma M, kaveri SV, Bayry J*. 2016. Orientation of the immune response by basophils. Revue Française d'Allergologie 56:117-119.

195.Singh BN, Saha C, Galun D, Upreti DK, Bayry J*, Kaveri SV*. 2016. European Viscum album: a potent phytotherapeutic agent with multifarious phytochemicals, pharmacological properties and clinical evidence. RSC Advances 6:23837-23857.

194. Maddur MS, Trinath J, Rabin M, Bolgert F, Guy M, Vallat JM, Magy L, Balaji KN, Kaveri SV, Bayry J*. 2015. Intravenous immunoglobulin-mediated expansion of regulatory T cells in autoimmune patients is associated with increased prostaglandin E2 levels in the circulation. Cellular & Molecular Immunology 12:650-652.

193. Stephen-Victor E, Saha C, Sharma M, Holla S, Balaji KN, Kaveri SV, Bayry J*. 2015. Inhibition of programmed death 1 ligand 1 on dendritic cells enhances Mycobacterium-mediated interferon γ (IFN-γ) production without modulating the frequencies of IFN-γ-producing CD4+ T cells. Journal of Infectious Diseases 211:1027-1029.

192. Sharma M, Stephen-Victor E, Poncet P, Kaveri SV, Bayry J*. 2015. Basophils are inept at promoting human Th17 responses. Human Immunology 76:176-180.

191. Saha C, Hegde P, Friboulet A, Bayry J, Kaveri SV. 2015. Viscum album-mediated COX-2 inhibition implicates destabilization of COX-2 mRNA. PLoS ONE 10: e0114965.

190. Bosschem I, Bayry J, De Bruyne E, Van Deun K, Smet A, Vercauteren G, Pasmans F, Ducatelle R, Haesebrouck, Flahou B. 2015. Effect of different adjuvants on protection and side-effects induced by Helicobacter suis whole-cell lysate vaccination. PLoS ONE 10: e0131364.

189. Hoseini-Alfatemi SM, Bayry J, Sharifi-Rad J. 2015. IgE response to two new allergen proteins of Solanum melongena L. (eggplant). Immunology Letters 168:268-270.

188. Hadzhieva M, Vassilev TL, Roumenina L, Bayry J, Kaveri SV, Lacroix-Desmazes S, Dimitrov JD. 2015. Mechanism and functional implications of heme-induced binding promiscuity of IgE. Biochemistry 54:2061-2072.

187. Sharma M, Bayry J*. 2015. Autoimmunity: Basophils in autoimmune and inflammatory diseases. Nature Reviews Rheumatology 11:129-131.

186. Galeotti C, Kaveri SV, Bayry J*. 2015. Molecular and immunological biomarkers to predict IVIg response. Trends in Molecular Medicine 21:145-147.

185. Bayry J*, Hartung HP, Kaveri SV. 2015. IVIg for relapsing-remitting multiple sclerosis: promises and uncertainties. Trends in Pharmacological Sciences 36:419-421.

184. Das M, Kaveri SV, Bayry J. 2015. Cross-presentation of antigens by dendritic cells: role of autophagy. Oncotarget 6:28527-28528.

183. Maddur MS, Bayry J*. 2015. B cells drive Th2 responses by instructing human dendritic cell maturation. Oncoimmunology 4:e1005508.

182. Elluru SR, Kaveri SV, Bayry J*. 2015. The protective role of immunoglobulins in fungal infections and inflammation. Seminars in Immunopathology 37:187-197.

181. Gilardin L, Bayry J, Kaveri SV. 2015. Intravenous immunoglobulin as clinical immune-modulating therapy. Canadian Medical Association Journal 187:257-264.

180. Elluru SR, Saha C, Hegde P, Friboulet A, Bayry J and Kaveri SV. 2015. Dissecting the anti-inflammatory effects of Viscum album: Inhibition of cytokine-induced expression of cyclooxygenase-2 and secretion of prostaglandin E2. In Mistletoe: From Mythology to Evidence-Based-Medicine (Edited by Zaenker KS, and Kaveri SV). Translational Research in Biomedicine vol 4. Karger Publisher. Page: 67-73.

179. Maddur MS, Sharma M, Hegde P, Stephen-Victor E, Pulendran B, Kaveri SV, Bayry J*. 2014.  Human B cells induce dendritic cell maturation and favour Th2 polarization by inducing OX-40 ligand. Nature Communications 5: 4092.

178. Sharma M, Schoindre Y, Hegde P, Saha C, Maddur MS, Stephen-Victor E, Gilardin L, Lecerf M, Bruneval P, Mouthon L, Benveniste O, Kaveri SV, Bayry J. 2014. Intravenous immunoglobulin-induced IL-33 is insufficient to mediate basophil expansion in autoimmune patients. Scientific Reports 4:  5672.

177. Bayry J, Beaussart A, Dufrêne Y, Sharma M, Bansal K, Kniemeyer O, Aimanianda V, Brakhage A, Kaveri SV, Kwon-Chung KJ, Latgé JP, Beauvais A. 2014. Surface structure characterization of Aspergillus fumigatus conidia mutated in the melanin synthesis pathway and their human cellular immune response. Infection & Immunity 82:3141-3153.

176. Othy S, Topçu S, Saha C, Kothapalli P, Lacroix-Desmazes S, Käsermann F, Miescher S, Bayry J*, Kaveri SV*. 2014. Sialylation may be dispensable for reciprocal modulation of helper T lymphocytes by intravenous immunoglobulin in experimental autoimmune encephalomyelitis. European Journal of Immunology 44:2059-2063.

175. Sharma M, Lecerf M, Friboulet A, Kaveri SV, Dissous C, Bayry J*. 2014. Mediation of T-helper 17 responses to schistosomes by dendritic cells but not basophils. Journal of Infectious Diseases  209:2019-2021.

174. Holla S, Kurowska-Stolarska M, Bayry J, Balaji KN. 2014. Selective inhibition of IFNG-induced autophagy by MIR155 and MIR31-responsive WNT5A and SHH signaling. Autophagy 10:311-330.

173. Patil V, Bayry J, Lacroix-desmazes S, Kazatchkine MD and Kaveri SV. 2014. Autoantibodies in therapeutic preparations of human intravenous immunoglobulin (IVIG). Autoantibodies 3rd Edition. Elsevier, Oxford. Page: 305-310.

172. Holla S, Sharma M, Vani J, Kaveri SV, Balaji KN, Bayry J*. 2014. GM-CSF along with IL-4 but not alone is indispensable for the differentiation of human dendritic cells from monocytes.  Journal of Allergy and Clinical Immunology 133:1500-1502.e1.

171. Maddur MS, Rabin M, Hegde P, Bolgert F, Guy M, Vallat JM, Magy L, Bayry J*, Kaveri SV*. 2014. Intravenous immunoglobulin exerts reciprocal regulation of Th1/Th17 cells and regulatory T cells in Guillain-Barré syndrome patients. Immunologic Research 60:320-329.

170. Gupta N, Hegde P, Lecerf M, Nain M, Kalia M, Vrati S, Bayry J, Lacroix-Desmazes S, Kaveri SV. 2014. Japanese encephalitis virus expands regulatory T cells by increasing the expression of PD-L1 on dendritic cells. European Journal of Immunology 44:1363-1374.

169. Patil PK, Sajjanar CM, Natarajan C, Bayry J*. 2014. Neutralizing antibody responses to foot-and-mouth disease quadrivalent (type O, A, C and Asia 1) vaccines in growing calves with pre-existing maternal antibodies. Veterinary Microbiology 169:233-235.

168. Dalmas E, Venteclef N, Caer C, Poitou C, CremerI, Aron-Winewsky J, Lacroix-Desmazes S, Bayry J, Kaveri SV, Clément K, André S, Guerre-Millo M. 2014. T cell-derived IL-22 amplifies IL-1β-driven inflammation in human adipose tissue: relevance to obesity and type 2 diabetes. Diabetes 63:1966-1977.

167. Bouhlal H, Martinvalet D, Teillaud JL, Fridman CS, Kazatchkine MD, Bayry J, Lacroix-Desmazes S, Kaveri SV. 2014. Natural autoantibodies to Fcγ receptors in intravenous immunoglobulins. Journal of Clinical Immunology 34:S4-S11.

166. Casulli S, Coignard H, Amazzough K, Shoai-Tehrani M, Bayry J, Mahlaoui N, Elbim C, Kaveri SV. 2014. Defective functions of polymorphonuclear neutrophils in patients with common variable immunodeficienct. Immunologic Research 60:69-76.

165. Elluru SR, Kaveri SV, Bayry J*. 2014. Regulation of human dendritic cell functions by natural anti-CD40 antibodies. Methods in Molecular Biology 1155: 47-54.

164. Pradhan V, Nadkar Milind, Rajadhyaksha A, Pandit P, Surve P, Lecerf M, Bayry J, Kaveri SV Gosh K. 2014. Clinical and autoimmune profile of Scleroderma patients from Western India. International Journal of Rheumatology 2014: 983781.

163. Bayry J*, Tartour E, Tough DF. 2014. Targeting CCR4 as an emerging strategy for cancer therapy and vaccines. Trends in Pharmacological Sciences 35:163-165.

162. Bayry J*. 2014. Regulatory T cells as adjuvant target for enhancing the viral disease vaccine efficacy. Virusdisease 25:18-25.

161. Von Gunten S, Shoenfeld Y, Blank M, Branch DR, Vassilev T, Käsermann F, Bayry J, Kaveri SV, Simon HU. 2014. IVIG pluripotency and the concept of Fc-sialylation: challenges to the scientist. Nature Reviews Immunology 14: 349.

160. Kaveri SV, Lecerf M, Saha C, Kazatchkine MD, Lacroix-Desmazes S, Bayry J. 2014. Intavenous immunoglobulin and immune response. Clinical & Experimental Immunology 178: 94-96.

159. Trinath J, Hegde P, Sharma M, Maddur MS, Rabin M, Vallat JM, Magy L, Balaji KN, Kaveri SV, Bayry J*. 2013. Intravenous immunoglobulin expands regulatory T cells via induction of cyclooxygenase-2-dependent prostaglandin E2 in human dendritic cells. Blood 122:1419-1427.

158. Sharma M, Hegde P, Aimanianda V, Beau R, Maddur MS, Sénéchal H, Poncet P, Latgé JP, Kaveri S, Bayry J*. 2013. Circulating human basophils lack the features of professional antigen presenting cells. Scientific Reports 3: 1188.

157. Othy S, Hegde P, Topçu S, Sharma M, Maddur MS, Lacroix-Desmazes S, Bayry J, Kaveri SV. 2013. Intravenous gammaglobulin inhibits encephalitogenic potential of pathogenic T cells and interferes with their trafficking to central nervous system implicating sphingosine-1 phosphate receptor 1-mammalian target of rapamycin axis. Journal of Immunology 190:4535-4541.

156. Trinath J, Hegde P, Balaji KN, Kaveri SV, Bayry J*. 2013. Intravenous immunoglobulin-mediated regulation of notch ligands on human dendritic cells. Journal of Allergy and Clinical Immunology 131:1255-1257, 1257.e1.

155. Maddur MS, Sharma M, Hegde P, Lacroix-Desmazes S, Kaveri SV, Bayry J*. 2013. Inhibitory effect of IVIG on IL-17 production by Th17 cells is independent of anti-IL-17 antibodies in the immunoglobulin preparations. Journal of Clinical Immunology 33: S62-S66.

154. Vani J, Shaila, MS, Trinath J, Balaji KN, Kaveri SV, Bayry J*. 2013. Mycobacterium tuberculosis cell wall-associated Rv3812 protein induces strong dendritic cell-mediated interferon γ responses and exhibits vaccine potential. Journal of Infectious Diseases 208:1034-1036.

153. Shevchenko I, Karakhanova S, Soltek S, Link J, Bayry J, Werner J, Umansky V , Bazhin A. 2013. Low-dose gemcitabine depletes regulatory T cells and improves survival in the orthotopic Panc02 model of pancreatic cancer. International Journal of Cancer 133:98-107.

152. Ghorpade DS, Holla S, Kaveri SV, Bayry J, Patil SA, Balaji KN. 2013.  Sonic hedgehog-dependent induction of microRNA-31 and microRNA-150 regulates M. bovis BCG-driven TLR2 signaling. Molecular and Cellular Biology 33:543-556.

151. Alsteens D, Aimanianda V, Hegde P, Pire S, Beau R, Bayry J, Latgé JP, Dufrêne YF. 2013. Unravellingthe nanoscale surface properties of chitin synthase mutants of Aspergillus fumigatus and their biological implications. Biophysics Journal. 105: 320-327.

150. Gupta N, LeGoff J, Chamat S, Mercier-Delarue S, Touzelet O, Power UF, Kazatchkine MD, Simon F, Lacroix-Desmazes S, Bayry J, Kaveri SV. 2013. Affinity-purified respiratory syncytial virus antibodies from intravenous immunoglobulin exert potent antibody-dependent cellular cytotoxicity. PLoS ONE 8: e69390.

149. Teyssandier M, André S, Gupta N, Dasgupta S, Bayry J, Kaveri SV, Lacroix-Desmazes S; ABRISK consortium 2013. Therapeutic factor VIII does not trigger TLR1.2 and TLR2.6 signalling in vitro. Haemophilia 19:399-402.

148. Sharma M, Kaveri SV, Bayry J. 2013*. Th17 cells, pathogenic or not? TGF-b3 imposes the embargo. Cellular & Molecular Immunology 10: 101-102.

147. Bayry J* and Radstake TR. 2013. Immune-mediated inflammatory diseases: progress in molecular pathogenesis and therapeutic strategies. Expert Review of Clinical Immunology 9:297-299

146. Bazhin A, Bayry J, Umansky V, Werner J, Karakhanova S. 2013. Overcoming immunosuppression as a new immunotherapeutic approach against pancreatic cancer. Oncoimmunology 2: e25736.

145. Bayry J*. 2013. Emerging viral diseases of livestock in the developing world. Indian Journal of Virology 24: 291-294.

144. Bayry J*. 2013. Journals: Open-access boom in developing nations. Nature 497:40.

143. Maddur MS, Kaveri SV, Bayry J*. 2012. Regulation of human dendritic cells by B cells depends on the signals they receive. Blood 119:3863-3864.

142. Othy S, Topçu S, Kaveri SV, Bayry J*. 2012. Effect of CC chemokine receptor 4 antagonism on the evolution of experimental autoimmune encephalomyelitis. Proceedings of the National Academy of Sciences USA 109: E2412-E2413.

141. Trinath J, Maddur MS, Kaveri SV, Balaji KN, Bayry J*. 2012. Mycobacterium tuberculosis promotes regulatory T-cell expansion via induction of programmed death-1 ligand 1 (PD-L1, CD274) on dendritic cells. Journal of Infectious Diseases 205:694-696. 

140. Othy S, Bruneval P, Topçu S, Dugail I, Delers F, Lacroix-Desmazes, Bayry J*, Kaveri SV*. 2012. Effect of IVIg on human dendritic cell-mediated antigen uptake and presentation: role of lipid accumulation. Journal of Autoimmunity 39: 168-172.

139. Vitali C, Mingozzi F, Broggi A, Barresi S, Zolezzi F, Bayry J, Raimondi G, Zanoni I, Granucci F. 2012. Migratory and not lymphoid-resident dendritic cells maintain peripheral self-tolerance and prevent autoimmunity via induction of iTreg cells. Blood 120:1237-1245.

138. Vani J, Kaveri SV, Bayry J*. 2012. Myeloid dendritic cell dysfunction during primary HIV-1 infection is independent of interaction with gp120. Journal of Infectious Diseases 205:1893-1895.

137. Vani J, Sharma M, Shaila MS, Kaveri SV, Bayry J*. 2012. Impact of gp120 on dendritic cell-derived chemokines: relevance for the efficacy of gp120-based vaccines for HIV-1. Clinical & Vaccine Immunology 19:1335-1336.

136. Bayry J*, Mouthon L, Kaveri SV. 2012. Intravenous immunoglobulin expands regulatory T cells in autoimmune rheumatic disease. Journal of Rheumatology 39:450-451.

135. Bayry J*, Aimanianda V, Guijarro JI, Sunde M, Latgé JP. 2012. Hydrophobins-unique fungal proteins. PLoS Pathogens 8:e1002700.

134. Bayry J*. 2012. Chemokine axis as a therapeutic target to enhance the recruitment of Tregs and treat organ-specific autoimmune and inflammatory diseases. Immunotherapy 4: 9-12.

133. Maddur MS, Miossec P, Kaveri SV, Bayry J*. 2012.  Th17 cells: biology, pathogenesis of autoimmune and inflammatory diseases, and therapeutic strategies. American Journal of Pathology 181:8-18.

132. Kaveri S*, Silverman GJ, Bayry J*. 2012. Natural IgM in immune equilibrium and harnessing their therapeutic potential. Journal of Immunology 188:939-945.

131. Pere H, Tanchot C, Bayry J, Terme M, Taieb J, Badoual C, Adotevi O, Merillon N, Marcheteau E, Quillien V, Banissi C, Carpentier A, Sandoval F, Nizard M, Quintin-Colonna F, Kroemer G, Fridman WH, Zitvogel L, Oudard S, Tartour E. 2012. Comprehensive analysis of current approaches to inhibit regulatory T cells in cancer. Oncoimmunology 1:326-333.

130. Bayry J*. 2012. Government: More credit due to India’s scientists. Nature 484:167.

129. Maddur MS, Vani J, Hegde P, Lacroix-Desmazes S, Kaveri S, Bayry J*. 2011. Inhibition of differentiation, amplification, and function of human TH17 cells by intravenous immunoglobulin. Journal of Allergy and Clinical Immunology 127:823-830.

128. Bayry J*, Fournier EM, Maddur MS, Vani J, Wootla B, Dimitrov JD, Sibéril S, Dimitrov JD, Lacroix-Desmazes S, Berdah M, Carbol Y, Oksenhendler E, Lévy Y, Mouthon L, Sautès-Fridman C, Hermine O, Kaveri SV. 2011. Intravenous immunoglobulin induces proliferation and immunoglobulin synthesis from B cells of patients with common variable immunodeficiency: A mechanism underlying the beneficial effect of IVIg in primary immunodeficiencies.  Journal of Autoimmunity 36: 9-15.

127. Pere H, Montier Y, Bayry J, Quintin-Colonna F, Merillon N, Dransart E, Badoual C, Gey A, Ravel P, Marcheteau E, Batteux F, Sandoval F, Adotevi O, Chiu C, Garcia S, Tanchot C, Lone YC, Ferreira LCS, Nelson BH, Hanahan D, Fridman WH, Johannes L, Tartour E. 2011. A CCR4 antagonist combined with vaccines induce antigen-specific CD8+ T cells and tumor immunity against self antigens. Blood 118: 4853-4862.

126. Maddur MS, Kaveri SV, Bayry J*. 2011. Comparison of different IVIg preparations on IL-17 production by human Th17 cells. Autoimmunity Reviews 10:809-810.

125. Maddur MS, Hegde P, Sharma M, Kaveri SV, Bayry J*. 2011. Human B cells are resistant to immunomodulation by ‘IVIg-educated’ dendritic cells. Autoimmunity Reviews 11:154-156.

124. Wootla B, Christophe OD, Mahendra A, Dimitrov JD, Repessé Y, Olivier V, Friboulet A, Borel-Derlon A, Levesque H, Borg JY, Andre S, Bayry J, Calvez T, Kaveri SV, Lacroix-Desmazes S. 2011. Proteolytic antibodies activate factor IX in patients with acquired haemophilia. Blood 117: 2257-2264.

123. Araujo LM, Chauvineau A, Zhu R, Diem S, Bourgeois E, Levescot A, Huerre M, Gombert JM, Bayry J, Daëron M, Bruhns P, Kaveri SV, Herbelin A. 2011. Cutting Edge: IVIg inhibits iNKT cell-mediated allergic airway inflammation through FcgRIIIA-dependent mechanisms. Journal of Immunology 186:3289-3293.

122. Navarrete AM, DelignatS, Teillaud JL, Kaveri SV, Lacroix-Desmazes, Bayry J*. 2011. CD4+CD25+ regulatory T cell-mediated changes in the expression of endocytic receptors and endocytosis process of human dendritic cells. Vaccine 29: 2649-2652.

121. Meslier Y, André S, Dimitrov JD, Deligant S, Bayry J, Kaveri SV, Lacroix-Desmazes S. 2011. Bortezomib delays the onset of factor VIII inhibitors in experimental hemophilia A, but fails to eliminate established anti-factor VIII IgG-producing cells. Journal of Thrombosis and Haemostasis 9:719-728.

120. Hegde P, Maddur M, Friboulet A, Bayry J, Kaveri SV. 2011. Viscum album exerts anti-inflammatory effect by selectively inhibiting cytokine-induced expression of cyclooxygenase-2. PLoS ONE 6: e26312.

119. Casulli S, Topçu S, Fattoum L von Gunten S, Simon HU, Teillaud JL, Bayry J, Kaveri SV, Elbim C. 2011. A differential concentration-dependent effect of IVIg on neutrophil functions: relevance for anti-microbial and anti-inflammatory mechanisms. PLoS ONE 6: e26469.

118. Bayry J*. 2011. New horizons in natural TNF-α antagonist research. Trends in Molecular Medicine 17:538-540.

117. Bayry J, Negi VS, Kaveri SV. 2011. Intravenous immunoglobulin therapy in rheumatic diseases. Nature Reviews Rheumatology 7:349-359.

116. Hegde NR*, Kaveri SV, Bayry J*. 2011. Recent advances in the administration of vaccines for infectious diseases: microneedles as painless delivery devices for mass vaccination. Drug Discovery Today 16:1061-1068.

115. Kaveri SV, Maddur MS, Hegde P, Lacroix-Desmazes S, Bayry J. 2011. Intravenous immunoglobulins in immunodeficiencies: more than mere replacement therapy. Clinical & Experimental Immunology 164 (Suppl. 2): 2-5.

114. Bayry J*, Kaveri SV, Follette P. 2011. Indian Science: steps to excellence. Science 331:29-30.

113. Bansal K, Elluru SE, Narayana Y, Chaturvedi R, Patil S, Kaveri SV, Bayry J*, Balaji KN*. 2010. PE_PGRS antigens of Mycobacterium tuberculosis induce maturation and activation of human dendritic cells. Journal of Immunology 184: 3495-3504.

112. Bansal K, Sinha AY, Ghorpade DS, Togarsimalemath SK, Patil S, Kaveri SV, Balaji KN*, Bayry J*. 2010. Src homology 3-interacting domain of Rv1917c of Mycobacterium tuberculosis induces selective maturation of human dendritic cells by regulating PI3K-MAPK-NF-kB signaling and drives Th2 responses. Journal of Biological Chemistry 285: 36511-36522.

111. Dimitrov JD, Dasgupta S, Navarrete AM, Delignat S, Repesse Y, Meslier, Y Planchais C, Teyssandier M, Motterlini R, Bayry J, Kaveri SV, Lacroix-Desmazes S. 2010. Induction of heme oxygenase-1 in factor VIII-deficient mice reduces the immune response to therapeutic factor VIII. Blood 115: 2682-2685.

110. Bénard A, Cavaillès P, J Boué, Chapey E, Bayry J, Blanpied C, Meyer N, Lamant L, Kaveri SV, Brousset P, Dietrich G. 2010. µ-opioid receptor is induced by IL-13 within lymph nodes from patients with Sézary syndrome. Journal of Investigative Dermatology 130: 1337-1344.

109. Othy S, Kazatchkine MD, Kaveri SV and Bayry J*. 2010. Intravenous immunoglobulin therapy for rheumatic diseases. CML Rheumatology 29:69-77.

108. Mouyna I, Kniemeyer O, Jank T, Loussert C, Mellado E, Aimanianda V, Beauvais A, Wartenberg D, Sarfati J, Bayry J, Prévost MC, Brakhage A, Strahl S, Huerre M, Latgé JP. 2010. Members of protein O-mannosyltransferase family in Aspergillus fumigatus differentially affect growth, morphogenesis and viability. Molecular Microbiology 76:1205-1221.

107. Kaveri SV, Mouthon L, Bayry J*. 2010. Basophils and nephritis in lupus. New England Journal of Medicine 363:1080-1082.

106. Maddur MS, Vani J, Lacroix-Desmazes S, Kaveri SV, Bayry J*. 2010. Autoimmunity as a predisposition for infectious diseases. PLoS Pathogens 6: e1001077.

105. Bayry J*. 2010. Immunology: TL1A in the inflammatory network in autoimmune diseases. Nature Reviews Rheumatology 6: 67-68.

104. Maddur MS, Kaveri SV, Bayry J*. 2010. Basophils as antigen presenting cells. Trends in Immunology 31:45-48.

103. Galeotti C, Bayry J, Kone-Paut I, Kaveri SV. 2010. Kawasaki disease: aetiopathogenesis and therapeutic utility of intravenous immunoglobulin. Autoimmunity Reviews 9: 441-448.

102. Navarrete AM, Dasgupta S, Teyssandier M, Repesse Y, Delignat S, Andre S, Bayry J, Kaveri SV, Lacroix-Desmazes S. 2010. Endocytic receptor for pro-coagulant factor VIII: Relevance to inhibitor formation. Thrombosis & Haemostasis 104: 1093-1098.

101. Maddur MS, Vani J, Dimitrov JD, Balaji KN, Lacroix-Desmazes S, Kaveri S, Bayry J. 2010. Dendritic cells in autoimmune diseases. Open Arthritis Journal 3: 1-7.

100. Maddur MS, Othy S, Hegde P, Vani J, Lacroix-Desmazes S, Bayry J, Kaveri SV. 2010. Immunomodulation by intravenous immunoglobulin: role of regulatory T cells. Journal of Clinical Immunology 30 (suppl 1): S4-S8.

99. Dimitrov JD, Kaveri SV, Bayry J*. 2010. Metrics: journal’s impact factor skewed by a single paper. Nature 466:179.

98. Aimanianda V*, Bayry J*, Bozza S, Kniemeyer O, Perruccio K, Elluru SR, Clavaud C, Paris S, Brakhage AA, Kaveri SV, RomaniL, Latgé JP. 2009. Surface hydrophobin prevents immune recognition of airborne fungal spores. Nature 460: 1117-1121.

97. Bayry J*, Bansal K, Kazatchkine MD, Kaveri S. 2009. DC-SIGN and a2,6-sialylated IgG Fc interaction is dispensable for the anti-inflammatory activity of IVIg on human dendritic cells. Proceedings of the National Academy of Sciences USA 106:E24.

96. Davies MN, Bayry J, Tchilian EZ, Vani J, Shaila MS, Forbes EK, Draper SJ, Beverley PCL, Tough DF, Flower DR 2009. Toward the discovery of vaccine adjuvants: Coupling in silico screening and in vitro analysis of antagonist binding to human and mouse CCR4 receptors. PLoS ONE 4: e8084.

95. Fernandez-Cruz E, Kaveri SV, Peter HH, DurandyA, Cantoni N, Quinti I, Sorensen R, Bussel J, Danieli G, Winkelmann A, Bayry J, Käsermann F, Späth P, Helbert M, Salama A, van Schaik IN and Yuki N. 2009. 6th International Immunoglobulin Symposium: Poster Presentations. Clinical & Experimental Immunology 158 (Suppl 1): 60-67.

94. Navarrete A, Dasgupta S, Delignat S, Caligiuri G, Christophe OD, Bayry J, Nicoletti A, Kaveri SV, Lacroix-Desmazes S. 2009. Splenic marginal zone antigen presenting cells are critical for the primary allo-immune response to therapeutic factor VIII in hemophilia A. Journal of Thrombosis and Haemostasis 7: 1816-1823.

93. Vani J, Shaila MS, Rao MKN, Krishnaswamy UM, Kaveri SV, Bayry J*. 2009. B lymphocytes from tuberculosis patients exhibit hampered antigen-specific responses with a concomitant over-expression of IL-8. Journal of Infectious Diseases 200: 481-482.

92. Dimitrov JD, Roumenina LT, Andre S, Repesse Y, Atanasov BP, Jacquemin M, Saint-Remy JM, Bayry J, Kaveri SV, Lacroix-Desmazes S. 2009. Kinetics and thermodynamics of interaction of coagulation factor VIII with a pathogenic human antibody. Molecular Immunology 47:290-297.

91. Mihaylova N, Voynova E, Tchorbanov A, Dolashka-Angelova P, Bayry J, Devreese B, Kaveri SV, Vassilev T. 2009. Simultaneous engagement of FcγIIb and CD22 inhibitory receptors silences targeted B cells and suppresses autoimmune disease activity. Molecular Immunology 47:123-130.

90. Wootla B, Mahendra A, Dimitrov JD, Friboulet A, Borel-Derlon A, Rao DN, Uda T, Borg JY, Bayry J, Kaveri SV, Lacroix-Desmazes S. 2009. Factor VIII-hydrolyzing IgG in acquired and congenital hemophilia. FEBS Letters 583: 2565-2572.

89. Hegde NR, Maddur MS, Rao PP, Kaveri SV, Bayry J*. 2009. Thermostable foot-and-mouth disease virus as vaccine candidate for endemic countries: a perspective. Vaccine 27: 2199-2201.

88. Bayry J. 2009*. Autoimmunity: CTLA-4: a key protein in autoimmunity. Nature Reviews Rheumatology 5:244-245.

87. Aimanianda V, Haensler J, Lacroix-Desmazes S, KaveriSV, Bayry J*.2009. Novel cellular and molecular mechanisms of induction of immune responses by aluminum adjuvants. Trends in Pharmacological Sciences 30: 287-295.

86. AndréS, Tough DF, Lacroix-Desmazes S, KaveriSV, Bayry J*.  2009. Surveillance of antigen-presenting cells by CD4+CD25+ regulatory T cells in autoimmunity: immunopathogenesis and therapeutic implications. American Journal of Pathology 174:1575-1887.

85. Hegde NR, Rap PP, Bayry J, Kaveri SV. 2009. Immunotherapy of viral infections. Immunotherapy 1: 691-711.

84. Maddur MS, Lacroix-Desmazes S, Bayry J, Kaveri S. 2009. Intravenous polyclonal immunoglobulin in autoimmune diseases: clinical indications and mechanisms of action. Drug Discov Today: Therapeutic Strategies. 6 (1): 5-11.

83. Hegde NR, Maddur MS, Kaveri SV, Bayry J*. 2009. Reasons to include viruses in the tree of life. Nature Reviews Microbiology 7: 615.

82. Vani J, Bansal K, Kazatchkine MD, Kaveri SV, Bayry J*. 2009. Immunointervention for patients with HIV and tuberculosis. Lancet Infectious Diseases 9:332-333.

81. Bayry J*, Tchilian EZ, Davies MN, Forbes EK, Draper SJ, Kaveri S, Hill AVS, Kazatchkine MD, Beverley PCL, Flower DR, Tough DF. 2008. In silico identified CCR4 antagonists target regulatory T cells and exert adjuvant activity in vaccination. Proceedings of the National Academy of Sciences USA 105: 10221-10226.

80. Ephrem, E, Chamat S, Miquel C, Fisson S, Mouthon L, Caligiuri G, Delignat S, Elluru S, Bayry J, Lacroix-Desmazes, Cohen JL, Salomon BL, Kazatchkine MD, Kaveri SV, Misra N. 2008. Expansion of CD4+CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis. Blood 111:715-722.

79. Elluru S, Duong van Huyen, Delignat S, Kazatchkine MD, Friboulet A, Kaveri SV, Bayry J*. 2008. Induction of maturation and activation of human dendritic cells: A mechanism underlying the beneficial effect of Viscum album as complimentary therapy cancer. BMC Cancer 8:161.

78. Wootla B, Dasgupta S, Dimitrov JD, Bayry J, Lévesque H, Borg J-Y, Borel-Derlon A, Rao DN, Friboulet A, Kaveri SV, Lacroix-Desmazes S. 2008. FVIII hydrolysis mediated by anti-FVIII autoantibodies in acquired hemophilia. Journal of Immunology 180: 7714-7720.

77. Dasgupta S, Navarrete AM, André S, Wootla B, DelignatS, Repessé Y, Bayry J, Nicoletti A, Saenko E, d’Oiron R, Jacquemin M, Saint-Remy JM, Kaveri SV, Lacroix-Desmazes S. 2008. Factor VIII bypasses CD91/LRP for endocytosis by dendritic cells leading to T cell activation. Haematologica 93:83-89.

76. Kaveri S, Lacroix-desmazes S, Bayry J. 2008. The antiinflammatory IgG. New England Journal of Medicine 359: 307-309.

75. Bayry J*. 2008. An immunologist applauds a protein that prunes intolerant white blood cells. Nature 456: 285.

74. Tha-In T, Bayry J, Metselaar HJ, Kaveri SV, Kwekkeboom J. 2008. Modulation of the cellular immune system by Intravenous Immunoglobulin. Trends in Immunology 29: 608-615.

73. Elluru S, Vani J, Delignat S, Bloch, MF, Lacroix-Desmazes S, Kazatchkine MD, Kaveri SV, Bayry J*. 2008. Modulation of human dendritic cell maturation and function by natural IgG antibodies. Autoimmunity Reviews 7: 487-490.

72. Lacroix-Desmazes S, Navarrete A-M, André S, Bayry J, Kaveri SV, Dasgupta S. 2008. Dynamics of factor VIII interactions determine its immunological fate in hemophilia A. Blood 112:240-249.

71. Dasgupta S, Bayry J, André S, Dimitrov JD, Kaveri SV, Lacroix-Desmazes S. 2008. Auditing protein therapeutics “management” by professional APCs: towards prevention of immune responses in replacement therapy. Journal of Immunology 181: 1609-1615.

70. Vani J, Elluru S, Negi VS, Lacroix-Desmazes S, Kazatchkine MD, Bayry J, Kaveri SV. 2008. Role of natural antibodies in immune homeostasis: IVIg perspctive. Autoimmunity Reviews 7: 440-444.

69. Bayry J*, Lacroix-desmazes S, Dasgupta S, Kazatchkine MD, Kaveri SV. 2008. Efficacy of regulatory T-cell immunotherapy: are inflammatory cytokines key determinants? Nature Reviews Immunology 8: 1p following 86.

68. Bayry J*, Flower DR, Tough DF, Kaveri SV. 2008. From ‘perfect mix’ to ‘potion magique’- regulatory T cells and anti-inflammatory cytokines as adjuvant targets. Nature Reviews Microbiology 6: C1.

67. Prost F, Duong-Van-Huyen JP, Elluru S, Deligant S, Bayry J, Kazatchkine MD and Kaveri SV. 2008. Molecular mechanisms underlying immunomodulatory effects of Viscum album preparations. Ethnopharmacology: Recent advances Page: 38-47.

66. Bayry J*, Triebel F, Kaveri SV, Tough DF. 2007. Human dendritic cells acquire a semimature phenotype and lymph node homing potential through interaction with CD4+CD25+ regulatory T cells. Journal of Immunology 178: 4184-4193.

65. Dasgupta S, Navarrete, AM, Bayry J, Delignat S, Wootla B, André S, Christophe O, Nascimbeni M, Jacquemin M, Martinez-Pomares L, Geijtenbeek TBH, Moris A, Saint-Remy JM, Kazatchkine MD, Kaveri SV, Lacroix-Desmazers S. 2007. A role for exposed mannosylations in presentation of human therapeutic self-proteins to CD4+ T lymphocytes. Proceedings of the National Academy of Sciences USA 104:8965-8970.

64. Dasgupta S, Repessé Y, Bayry J, Navarrete, AM, Wootla B, Delignat S, Irinopoulou, T, Kamaté C, Saint-Remy JM, Jacquemin M, Lenting PJ, Borel-Derlon A, Kaveri SV, Lacroix-Desmazers S. 2007. VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors. Blood 109: 610-612.

63. Delignat S, Dasgupta S, André S, Navarrete AM, Kaveri SV, Bayry J, André MH, Chtourou S, Tellier Z, Lacroix-Desmazes S. 2007. Comparison of the immunogenicity of different therapeutic preparations of human factor VIII in the murine model of hemophilia A. Haematologica 92: 1423-1426.

62. Dasgupta S, Bayry J, Kaveri SV and Lacroix-Desmazes S. 2007. Importance des sucres mannosyles pour la presentation de proteins du soi thérapeutiques aux lymphocytes T CD4+. SFI Actualités 116: 6-8.

61. Dimitrov JD, Bayry J, Sibéril S, Kaveri SV. 2007. Sialylated therapeutic IgG: A sweet remedy for inflammatory diseases? Nephrology Dialysis & Transplantation 22: 1301-1304.

60. Graff-Dubois S, Sibéril S, Elluru S, Negi VS, Deligant S, Mouthon L, Lacroix-Desmazes S, Kazatchkine MD, Bayary J and Kaveri SV. 2007. Utilisation des immunoglobulines polyclonales intraveineuses dans les pathologies auto-immunes et inflammatoires Transfusion Clinique et Biologique 14:63-68

59. Bayry J*, Kazatchkine MD, Kaveri SV. 2007. Shortage of human intravenous immunoglobulin: reasons and possible solutions. Nature Clinical Practice Neurology (Nature Reviews Neurology) 3:120-121.

58. Bayry J*, Lacroix-desmazes S Kazatchkine MD, Kaveri SV*. 2007. Monoclonal antibody and intravenous immunoglobulin therapy for rheumatic diseases: rationale and mechanisms of action. Nature Clinical Practice Rheumatology (Nature Reviews Rheumatology) 3:262-272.

57. Bayry J*, Sibéril S, Triebel F, Tough DF, Kaveri SV. 2007. Rescuing the CD4+CD25+ regulatory T cell functions in rheumatoid arthritis by cytokine-targeted monoclonal antibody therapy. Drug Discovery Today 12:548-552.

56. Negi VS, Elluru S, Sibéril S, Graff-Dubois S, Mouthon L, Kazatchkine MD, Lacroix-Desmazes S, Bayry J, Kaveri SV. 2007. Intravenous Immunoglobulin: An update on the clinical use and mechanisms of action. Journal of Clinical Immunology 27:233-245.

55. Dasgupta S, Bayry J, Lacroix-Desmazes S, Kaveri SV. 2007. Human mannose receptor (CD206) in immune response: novel insights into vaccination strategies using a humanized mouse model. Expert Review of Clinical Immunology 3: 677-681.

54. Sibéril S, Elluru S, Graff-Dubois S, Negi VS, Deligant S, Mouthon L, Lacroix-Desmazes S, Kazatchkine MD, Bayry J, Kaveri SV. 2007. IVIg in autoimmune and inflammatory diseases: A mechanistic perspective. Annals of the New York Academy of Sciences 1110: 497-506.

53. Sibéril S, Elluru S, Negi VS, Ephrem A, Misra N, Deligant S, Bayary J, Lacroix-Desmazes S, Kazatchkine MD and Kaveri SV. 2007. Intravenous immunoglobulin in autoimmune and inflammatory diseases: more than mere transfer of antibodies. Transfusion and Apheresis Science 37: 103-107

52. Lacroix-Desmazes S, Wootla B, Dasgupta S, Delignat S, Bayry J, Reinbolt J, Hoebeke J, Saenko EL, Kazatchkine MD, Friboulet, A, Christophe O, Nagaraja V, Kaveri SV. 2006. Catalytic IgG from patients with hemophilia A inactivate therapeutic factor VIII. Journal of Immunology 177:1355-1363.

51. Elluru S, Duong-Van-Huyen JP, Prost F, Delignat S, Bayry J, Ephrem A, Siberil S, Misra N, Lacroix-Desmazes S, Kazatchkine MD, Kaveri SV. 2006. Comparative study of the anti-inflammatory effect of two intravenous immunoglobulin preparations manufactured by different processes. Immunology Letters 107: 58-62.

50. Elluru S, Van Huyen JP, Delignat S, Prost F, Bayry J, Kazatchkine MD, Kaveri S. 2006. Molecular mechanisms underlying the immunomodulatory effects of mistletoe (viscum album L.) extracts Iscador. Arzneimittelforschung-Drug Research 56:461-466.

49. Duong-Van-Huyen JP, Delignat S, Bayry J, Kazatchkine MD, Bruneval P, Nicoletti A, Kaveri SV. 2006. Interleukin-12 is associated with the in vivo anti-tumor effect of mistletoe extracts in B16 mouse melanoma Cancer Letters  243:32-37.

48. Bayry J*, Tough DF. 2006. Interaction of foot-and-mouth disease virus with dendritic cells. Trends in Microbiology 14: 346-347.

47. Bayry J, Dasgupta S, Misra N, Ephrem A, Van Huyen JP, Delignat S, Hassan G, Caligiuri G, Nicoletti A, Lacroix-Desmazes S, Kazatchkine MD, Kaveri S. 2006. Intravenous immunoglobulin in autoimmune disorders: an insight into the immunoregulatory mechanisms. International Immunopharmacology 6:528-234.

46. Lacroix-Desmazes S, Bayry J, Kaveri SV, Hayon-Sonsino D, Thorenoor N, Charpentier J, Luyt CE, Mira JP,Nagaraja V, Kazatchkine MD, Dhainaut JF, Mallet VO. 2005. High levels of catalytic antibodies correlate with favorable outcome in sepsis. Proceedings of the National Academy of Sciences USA 102: 4109-4113.

45. Bayry J*, Lacroix-Desmazes S, Hermine O, Oksenhendler E, Kazatchkine MD, Kaveri SV. 2005. Amelioration of differentiation of dendritic cells from CVID patients by intravenous immunoglobulin. American Journal of Medicine 118: 1440-1441.

44. Bayry J*, Goudar MS, Nighot PK, Kshirsagar SG, Ladman BS, Gelb Jr J, Ghalsasi GR, Kolte GN. 2005. Emergence of a nephropathogenic avian infectious bronchitis virus with a novel genotype in India. Journal of Clinical Microbiology 43: 916-918.

43. Bayry J*, Lacroix-Desmazes S, Kazatchkine MD, Hermine O, Tough DF, Kaveri SV. 2005. Modulation of dendritic cell maturation and function by B lymphocytes. Journal of Immunology 175: 15-20.

42. Bayry J, Hermine O, Webster DA, Lévy Y, Kaveri SV. 2005. Common variable immunodeficiency: the immune system in chaos. Trends in Molecular Medicine 11: 369-375.

41. Bayry J, Misra N, Dasgupta S, Lacroix-Desmazes S, Kazatchkine MD, Kaveri SV. 2005. Natural autoantibodies: immune homeostasis and therapeutic intervention. Expert Review of Clinical Immunology 1: 213-222.

40. Misra N, Bayry J, Dasgupta S, EPhrem A, Van Huyen LPD, Delignat S, Hassan G, Caligiuri G, Nicoleti A, Lacroix-Desmazes S, Kazatchkine MD, Kaveri SV. 2005. Intravenous immunoglobulin and dendritic cells. Clinical Reviews in Allergy and Immunology 29: 201-205.

39. Ephrem A, Bayry J, Misra M, Dasgupta S, Wootla B, Van Huyen JP, Hassan G, Delignat S, Chamat S, Kaveri SV. 2005. Immunoglobulin-dependent regulation of dendritic cells in the context of autoimmune responses. Transfusion Medicine and Hemotherapy 32:369–372.

38. Misra N, Bayry J, Ephrem A, Dasgupta S, Delignat S, Doung Van Huyen JP, Prost F, Lacroix-Desmazes S, Nicoletti A, Kazatchkine MD, Kaveri SV. 2005. Intravennous immunoglobulins in neurological disorders: A mechanistic perspective. Journal of Neurology 252: i1-6.

37. Bayry J*, Tough DF. 2005. Is RNA interference feasible for the control of foot-and-mouth disease outbreaks? Trends in Immunology 26: 238-239.

36. Bayry J, Lacroix-Desmazes S, Donkova-Petrini V, Carbonneil C, Misra N, Lepelletier Y, Delignat S,Varambally S, Oksenhendler E, Lévy Y, Debré M, Kazatchkine MD, Hermine O, Kaveri SV. 2004. Natural antibodies sustain differentiation and maturation of human dendritic cells. Proceedings of the National Academy of Sciences USA 101: 14210-14215.

35. Bayry J, Lacroix-Desmazes S, Kazatchkine MD, Galicier L, Lepelletier Y, Webster D, Lévy, Y, Eibl MM, Oksenhendler E, Hermine O, Kaveri SV. 2004. Common variable immunodeficiency is associated with defective functions of dendritic cells. Blood 104: 2441-2443.

34. Misra, N, Bayry J, Lacroix-Desmazes S, Kazatchkine MD, Kaveri SV. 2004. Cutting Edge: Human CD4+CD25+ T cells restrain the maturation and antigen-presenting function of dendritic cells. Journal of Immunology 172: 4676-4680.

33. Varambally S, Bar-Dayan Y, Bayry J, Lacroix-Desmazes S, Horn M, Sorel M, Bar-Dayan Y, Ruberti G, Kazatchkine MD, Kaveri SV. 2004. Natural human polyreactive IgM induce apoptosis of lymphoid cell lines and of human peripheral blood mononuclear cells. International Immunology 16: 517-524.

32. Bayry J, Lacroix-Desmazes S, Kazatchkine MD, Kaveri SV. 2004. Intravenous immunoglobulin for infectious diseases: back to pre-antibiotic and passive prophylaxis era? Trends in Pharmacological Sciences 25: 306-310.

31. Bayry J, Thirion M, Delignat S, Misra N, Lacroix-Desmazes S, Kazatchkine MD, Kaveri SV. 2004. Dendritic cells and autoimmunity. Autoimmunity Reviews 3: 183-187.

30. Bayry J, Misra N, Ephrem A, Nicoletti A, Lacroix-Desmazes S, M.D. Kazatchkine MD and Kaveri SV. 2004. Beneficial aspects of natural autoantibodies. From Animal Models to Human Genetics: Research on the Induction and Pathogenicity of Autoantibodies. Autoantigens autoantibodies autoimmunity Vol 4; Page: 112-117.

29. Bayry J,Lacroix-Desmazes S,Carbonneil C,Misra N,Donkova V,Pashov A, Chevailler A, Mouthon L, Weill B, Bruneval P,Kazatchkine MD, Kaveri SV. 2003. Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin. Blood 101: 758-765.

28. Bayry J, Lacroix-Desmazes S, Delignat S, Mouthon L, Weill B, Kazatchkine MD, Kaveri SV. 2003. Intravenous immunoglobulin abrogates dendritic cell differentiation induced by IFN-a present in serum from patients with systemic lupus erythematosus. Arthritis & Rheumatism 48: 3497-3502.

27. Misra, N, Bayry J, Pashov, A, Kaveri SV, d’Oiron, R, Stieltjes, N, Roussel-Robert V, Kazatchkine MD, Boyer, O, Lacroix-Desmazes S. 2003. Restricted BV gene usage by Factor VIII-reactive CD4+ T cells in inhibitor-positive patients with severe hemophilia A. Thrombosis & Haemostasis 90: 813-822.

26. Lacroix-Desmazes S, Bayry J, Misra N, Artaud C, Kazatchkine MD and Kaveri SV. 2003. Anticorps catalytiques dirigés contre le facteur VIII chez les patients hémophiles A. Médecine Clinique 3: 209-212.

25. Bayry J, Misra N, Lacroix-Desmazes S, Kazatchkine, MD and Kaveri SV.  2003.  Immunoglobulin therapy of autoimmune and inflammatory diseases. Biomedical Progress: Clinical trends in Coagulation, Fibrinolysis and Immunology 16: 31-35.

24. Lacroix-Desmazes S, Bayry J, Kazatchkine, M D and Kaveri SV. 2003. Anticorps catalytiques ou abzymes (catalytic antibodies or “abzymes”). Med Sci. 19: 519-22.

23. Kohler H, Bayry J, Nicoletti A, Kaveri SV. 2003. Natural antibodies as tools to predict the outcome of immune response? Scandinavian Journal of Immunology 58: 285-289.

22. Bayry J, Lacroix-Desmazes S, Pashov A, Stahl D, Hoebeke J, Kazatchkine, MD, Kaveri SV. 2003. Autoantibodies to factor VIII with catalytic activity. Autoimmunity Reviews 2: 30-35.

21. Bayry J, Misra N, Latry V, Prost F, Delignat S, Lacroix-Desmazes S, Kazatchkine MD,  Kaveri SV. 2003. Mechanisms of action of intravenous immunoglobulin in autoimmune and inflammatory diseases. Transfusion Clinique et Biologique 10: 165-169.

20. Latry V, Bayry J, Thorenoor N, Kazatchkine MD, Kaveri SV, Lacroix-Desmazes S. 2003. Biological functions of catalytic antibodies. Transfusion Medicine and Hemotherapy 30:264-267.

19. Bayry J, Thirion M, Misra N, Thorenoor N, Delignat S, Lacroix-Desmazes S, Bellon B, Kaveri S,  Kazatchkine MD. 2003. Mechanisms of action of intravenous immunoglobulin in autoimmune and inflammatory diseases. Neurological Sciences 24:S217-5221.

18. Kazatchkine MD, Bayry, J, Lacroix-Desmazes S and Kaveri SV. 2003. Mechanisms of action of intravenous immunoglobulin in autoimmune and inflammatory diseases. Intravenous immunoglobulins in the third millennium. Page: 105-112.

17. Lacroix-Desmazes S, Bayry J, Misra N, Horn MP, Villard S, Pashov A, Stieltjes N, d'Oiron R, Saint-Remy JM, Hoebeke J, Kazatchkine MD, Kaveri SV. 2002. The prevalence of proteolytic antibodies against factor VIII in hemophilia A. New England Journal of Medicine 346: 662-667.

16. Patil PK, Bayry J*, Ramakrishna C, Hugar B, Misra LD, Prabhudas K, Natarajan C. 2002 Immune responses of sheep to quadrivalent double emulsion foot-and-mouth disease vaccines: Rate of development of immunity and variations among other ruminants. Journal of Clinical Microbiology 40: 4367-4371.

15. Lacroix-Desmazes S, Moreau A, Bayry J, Kazatchkine MD and Kaveri SV. 2002. Hydrolytic activity of F VIII inhibitors in haemophilia A patients. Hématologie 8: 422-426.

14. Patil PK, Bayry J*, Ramakrishna C, Hugar B, Misra LD, Natarajan C. 2002 Immune responses of goats against foot-and-mouth disease quadrivalent vaccine: comparison of double oil emulsion and aluminium hydroxide gel vaccines in eliciting immunity. Vaccine 20: 2781-2789.

13. Bayry J, Lacroix-Desmazes S, Stahl D, Misra N, Delignat S, Donkova V, Pashov A, Kazatchkine, MD and Kaveri SV. 2002. Antibodies with catalytic activity. Autoantigens autoantibodies autoimmunity 3: 280-287.

12. Bayry J, Pashov A, Donkova V, Delignat S, Vassilev T, Stahl D, Bellon B, Kazatchkine, MD, Lacroix-Desmazes S and Kaveri SV. 2002. Immunomodulation of autoimmunity by intravenous immunoglobulin through interaction with immune networks. Vox Sanguinis 83: 49-52.

11. Patil PK, Bayry J*, Nair SP, Gopalakrishna S, Misra LD, Natarajan C. 2002. Early antibody responses of cattle for foot-and-mouth disease quadrivalent double oil emulsion vaccine. Veterinary Microbiology 87: 103-109.

10. Patil PK, Suryanarayana V, Bist P, Bayry J, Natarajan C. 2002. Integrity of GH-loop of foot-and-mouth disease virus during virus inactivation: detection by epitope specific antibodies. Vaccine 20: 1163-1168.

9. Duong-Van-Huyen JP, Bayry J, Delignat S, GastonAT, Michel O, Bruneval P, Kazatchkine MD, Nicoletti, A, Kaveri SV. 2002. Induction of endothelial cells apoptosis by Viscum album: A role for anti-tumoral properties of mistletoe lectins. Molecular Medicine 8: 600-606.

8. Lacroix-Desmazes S, Misra N, Bayry J, Villard S, Kazatchkine, MD, Kaveri SV. 2002. Antibodies with hydrolytic activity towards factor VIII in patients with hemophilia A. Journal of Immunological Methods 269: 251-256.

7. Lacroix-Desmazes S, Misra N, Bayry J, Mohanty D, Kaveri SV, Kazatchkine, MD. 2002. Autoantibodies to factor VIII. Autoimmunity Reviews 1: 105-110.

6. Lacroix-Desmazes S, Misra N, Bayry J, Artaud C, Drayton B, Kaveri SV, Kazatchkine MD.  2002. Pathophysiology of inhibitors to factor VIII in patients with Hemophilia. Haemophilia 8: 273-279.

5. Lacroix-Desmazes S, Bayry J, Misra N, Kaveri SV, Kazatchkine, MD. 2002. The concept of idiotypic vaccination against FVIII inhibitors in haemophilia A. Haemophilia 8: 55-59.

4. Bayry J* and Kaveri SV. 2001. Foot and mouth disease: a revised policy is required. Journal of Clinical Microbiology. 39: 3808.

3. Bayry J, Prabhudas K, Bist P, Reddy GR, Suryanarayana VV. 1999. Immuno affinity purification of foot and mouth disease virus type specific antibodies using recombinant protein adsorbed to polystyrene wells. Journal of Virological Methods 81: 21-30.

2. Bayry J, Indi S, Prabhudas K, Suryanarayana VV. 1999. Preparation of ISCOMs with urea solubilised recombinant FMDV protein. Vaccine 17: 2333-2334

1. Bayry J, Prabhudas K, Gopalakrishna S, Patil PK, Ramakrishna C, Misra LD, Suryanarayana VV. 1999. Protective immune response to 16 kDa immunoreactive recombinant protein encoding the C-terminal VP1 portion of Foot and Mouth Disease Virus type Asia 1. Microbiology & Immunology 43: 765-771.